Navigation Links
Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
Date:7/5/2011

TUESDAY, July 5 (HealthDay News) -- A drug designed to treat certain patients with non-small cell lung cancer boosts survival time without progression of cancer by several months, according to a new study.

The findings reveal that the drug, known as erlotinib (brand name Tarceva), doesn't just boost lifespan, said Dr. Neal E. Ready, associate professor of medical oncology at Duke Cancer Institute, who was not involved with the study. "What you really get is a prolonged period of time when the cancer is under control and someone has a really good quality of life."

This study is the first of its kind to look at Western patients. "Although a growing body of evidence has been emerging about this type of lung cancer, almost all of the studies have been conducted in Asian patients, a group that historically has had significantly different results to [non-small cell lung cancer] therapy compared to Western populations," said principal investigator Dr. Radj Gervais, of the Centre Francois Baclesse in Caen, France, in a news release from the International Association for the Study of Lung Cancer. The association is hosting the World Conference on Lung Cancer in Amsterdam, where the study results were scheduled for presentation Tuesday.

The study of the drug is a phase 3 study. That means it's in the final of three stages of testing that drugs undergo before they can be approved for treatment of a specific disease.

The researchers randomly assigned 174 patients to either erlotinib or platinum-based chemotherapy. Preliminary results showed that about 55 percent of patients responded to the drug, compared to nearly 11 percent to chemotherapy. Patients lived without progression of cancer for 9.4 months with the drug compared to 5.2 months for those who received chemotherapy.

And the median survival was 22.9 months for those who took the drug compared to 18.8 months for those on chemotherapy, the investigators found.

"Our results showed that first-line erlotinib nearly doubled progression-free survival; that's a significant improvement over chemotherapy, with a better tolerability profile," Gervais said in the news release.

Commenting on the findings, Ready pointed out that the research is important because it shows the value of targeting treatment towards patients with specific types of non-small cell cancer. "In oncology as a field, we're trying to move to identify the right treatment for the right patient," he said.

Erlotinib's side effects -- including an acne-type rash and diarrhea -- are easier to control than those of chemotherapy, he added. As for expense, Ready noted, oral therapies, like this one, tend to be as costly or less expensive than chemotherapy, considering that they cause fewer side effects that need to be managed.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

For more about lung cancer, visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: International Association for the Study of Lung Cancer, news release, July 5, 2011; Neal E. Ready, M.D., associate professor of medical oncology, Duke Cancer Institute, Durham, N.C.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Vaccine Seems to Cure Prostate Cancer in Mice
2. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
3. Ex-Dallas Maverick survives rare form of leukemia thanks to experimental drug treatment
4. Experimental treatment offers relief from painful prostate condition
5. Christos Mantzoros honored by Federation of the American Societies for Experimental Biology
6. Experimental Test May Warn of Premature Births
7. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
8. Experimental Weight-Loss Drug Seems to Work: Study
9. Experimental drug achieves unprecedented weight loss
10. Science at a glance: Symposia, research and special events at Experimental Biology 2011
11. A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis ... global supply chains, has published the first annual edition of its Global ... more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that ... ... Risk & Performance Index ...
Breaking Medicine Technology: